

Amendment

U.S. Serial No. 09/435,992

Atty Reference: 037003-0275478

64. The method of claim 62 wherein said lymphoma is Hodgkin's disease.
65. The method of claim 61 wherein said leukemia is selected from the group consisting of chronic B cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Burkitt's type leukemia and monocytic cell leukemia.
66. The method of claim 60 wherein said anti-CD20 antibody is Rituxan®.
67. The method of claim 60 wherein said anti-CD40L antibody is a humanized or chimeric anti-CD40L antibody.
68. The method of claim 67 wherein said humanized anti-CD40L antibody is I?DEC-131.
69. The method of claim 60 wherein said anti-CD20 antibody is radiolabeled.
70. The method of claim 69 wherein said radiolabeled is ⁹⁰Y.
71. The method of claim 60 which includes the administration of at least one chemotherapeutic agent.
72. The method of claim 71 wherein said chemotherapeutic agent is selected from the group consisting of vincristine, prednisone, anthracycline, cyclophosphamide, asparaginase, fludarabine monophosphate, 2-chlorodeoxy adenosine, pertostate, metrotrexate, chlorambicil, 2-CDA, 2'-deoxy-coformycin, cytosine arabinoside, cisplatin, etoposide, procarbazine ifosfamide.
73. The method of claim 71 wherein said chemotherapeutic agent is an alkylating agent.
74. The method of claim 71 wherein said chemotherapeutic agent is a vinca alkaloid.
75. The method of claim 71 wherein said chemotherapeutic is a procarbazine.
76. The method of claim 71 wherein the method comprises administration of a combination of chemotherapeutic agents.
77. The method of claim 76 wherein said combinations are selected from the group consisting of MOPP, ABVD, CHVPP, CABS, MOPP plus ABVD, MOPP plus ABV, BCVPP, VABCD, ABDIC, CBVD, PCVP, CEP, EVA, MOPLACE, MIME, MINE, CEM, MTX-CHOP, EVAP or EPOCH.
78. The method of claim 76 wherein said combination are selected from the group consisting of CVP, CHOP, C-MOPP, CAP-BOP, m-BACOD, ProMACE-MOPP, ProMACE-CytaBOM, MACOP-B, IMVP-16, MIME, DHAP, ESHAP, CEPP (B) or CAMP.

Amendment

U.S. Serial No. 09/435,992

Atty Reference: 037003-0275478

79. The method of claim 61 which includes administration of a chemotherapeutic selected from the group consisting of vincristine, prednisone, anthracyclis, cyclophosphamide and aspraginase.
80. The method of claim 60 wherein the anti-CD20 antibody is administered prior to the anti-CD40L antibody.
81. The method of claim 60 wherein the anti-CD20 antibody is administered after the anti-CD40L antibody.
82. The method of claim 80 wherein the anti-CD20 antibody is Rituxan®.
83. The method of claim 81 wherein the anti-CD20 antibody is Rituxan®.
84. The method of claim 80 which includes chemotherapy.
85. The method of claim 80 which includes chemotherapy.
-